A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis

Human Gene Therapy

Volumn 9, Issue 6, 1998, Pages 889-909

  Wagner, John A ^a   Moran, Mary Lynn ^b   Messner, Anna H ^a   Daifuku, Richard ^c   Conrad, Carol K ^a   Reynolds, Thomas ^c   Guggino, William B ^d   Moss, Richard B ^a   Carter, Barrie J ^c   Wine, Jeffrey J ^e   Flotte, Terence R ^f   Gardner, Phyllis ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stanford Univ School of Medicine ^*  (United States)

^c Targeted Genetics Corporation   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS; CHRONIC SINUSITIS; CLINICAL TRIAL; CLONING VECTOR; CYSTIC FIBROSIS; GENE TARGETING; GENE THERAPY; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; RISK BENEFIT ANALYSIS;

ADENO-ASSOCIATED VIRUS;

EID: 17344363322     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1998.9.6-889     Document Type: Review

References (19)

1. Koch C, Hoiby N. The pathogenesis of cystic fibrosis. Lancet. 1993; 341:1065-1069.
2. Rosenfeld MA, Ronald G, Crystal RG. Gene therapy for pulmonary disease. Pathol Biol. 1993; 41(8):677-680.
3. Crystal RG. Gene therapy strategies for pulmonary disease. Am J Med. 1992; 92(Suppl 6A):44S-52S.
4. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr. 1993; 122(1):1-9.
5. Ramsey B, Richardson MA. Impact of sinusitis in cystic fibrosis. J Allergy Clin Immunol. 1992; 30(3 Pt 2):547-552.
6. Cepero R, Smith RJ, Catlin FI et al. Cystic fibrosis an otolaryngologic perspective. Otolaryngol Head Neck Surg. 1987; 97(4):356-360.
7. Cuyler JP, Monaghan AJ. Cystic fibrosis and sinusitis. J Otolaryngol. 1989; 18:173-175.
8. Wine JJ, King VV, Lewiston NJ. Method for rapid evaluation of topically applied agents to cystic fibrosis airways. Am J Physiol. 1991; 261:L218-L221.
9. Crystal RG, McElvaney NG, Rosenfeld MA et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genetics. 1994; 8:42-51.
10. Flotte TR, Afione SA, Solow R et al. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem. 1993; 268(5):3781-3790.
11. Flotte TR, Afione SA, Conrad C et al. Stable in vivo expression of the cystic fibrosis transmembrane regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA. 1993; 90:10610-10617.
12. Caplen NJ, Alton EWFW, Middleton PG et al. Liposome mediated CFTR gene transfer to the nasal epithelium of the patients with cystic fibrosis. Nature Med. 1995; 1:39-46.
13. Carter BJ. Adeno-associated virus vectors. Curr Opin Biotechnol. 1992; 3:53-59.
14. Muzcyzka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol. 1992; 158:97-129.
15. Egan M, Flotte T, Afione S et al. Defective regulation of outwardly rectifying chloride channels by protein kinase A corrected by insertion of CFTR. Nature. 1992; 358:581-584.
16. Flotte TR, Solow R, Owens RA et al. Gene expression from adeno-associated virus vectors in airway epithelial cells. Am J Respir Cell Mol Biol. 1992; 7:349-356.
17. Duffy SW. Asymptotic and exact power for the McNemar test and its analog with R controls per case. Biometrics. 1984; 40:1005-1015.
18. Daly L. Simple SAS macros for the calculation of exact binomial and Poisson confidence limits. Comput Biol Med. 1992; 22:351-361.
19. Fleiss JL. Statistical methods for rates and proportions. Wiley, New York. 1981.